Facebook
X
LinkedIn
ForwardTheranostics in Practice: From Program Requirements to Therapy-Ready Solutions
Radiation oncology is playing an increasingly important role in theranostics—but building a successful program requires more than clinical interest alone. From infrastructure and workflow to radiation safety and regulatory considerations, sites must be prepared to support safe, efficient, and scalable delivery.
In this webinar, gain practical insights into what it takes to stand up and operationalize a theranostics program, including real-world challenges, requirements, and lessons learned. The session will conclude with a look at how therapy-ready, turnkey solutions can help streamline implementation—bringing together the software, instrumentation, and expertise needed to move from planning to practice with confidence.
Live webinar: April 2, 2026 at 3:00 p.m. Eastern Time.
This activity is available from March 24, 2026, through 11:59 p.m. Eastern time on August 23, 2026.
Target Audience
This course is designed to meet the interest of radiation oncologists, radiation physicists and residents.
Learning Objectives
This activity addresses both current practice and forward-looking developments in RPT including:
- TBD
- TBD
- TBD
Moderator:
- Jeffrey Kapatoes, PhD - Mirion Technologies
Speakers
- Robert Hobbs, PhD, DABR, FAAPM, is an Associate Professor and Medical Physicist in the Department of Radiation Oncology at Johns Hopkins. Dr. Hobbs earned his undergraduate degrees in physics from the Université Louis Pasteur in Strasbourg, France and his PhD from the University of New Mexico in high energy physics.
Dr. Hobbs is the chairman of the AAPM Radiopharmaceutical Therapy sub-Committee, and serves on a number of committees and task groups that further the development, use, and education of radiopharmaceutical therapy and dosimetry for a wide range of national and international organizations. Most recently he has been awarded the 2025 MIRD Loevinger-Berman award. - Ravi Shridhar, MD, PhD, is the Theranostic Program Director in the Department of Radiation Oncology at the Advent Health Cancer Institute in Orlando. Dr. Shridhar is a board-certified radiation oncologist practicing for 17 years who specializes in the treatment of gastrointestinal, genitourinary, and thoracic malignancies. He has been instrumental in leading and overseeing treatment programs of Y90 for liver cancer and metastases. He oversaw the implementation of Lutathera for treatment of neuroendocrine carcinomas and Pluvicto for treatment of metastatic prostate cancer. His program is active in Theranostic clinical trials.
Continuing medical education credit is not available for this activity.
Price
Acknowledgement
By registering for and accessing the Webinar, I acknowledge that the content has been prepared by the Webinar Sponsor, does not necessarily reflect the views of ASTRO, does not imply endorsement of the Webinar Sponsor or its products by ASTRO, and is being offered solely for the educational benefit of its viewers.
Data Use
If you are located outside of the United States, please complete this consent form.
If you are located within the United States, by registering for and accessing this webinar, I understand that my name, job title, profession, professional affiliation and location (collectively “Data”) will be shared with the sponsor of this webinar who may use this Data to provide follow-up correspondence, post-webinar surveys and marketing materials.
Policies
The activity and its materials will only be available on the ASTRO website until August 23, 2026, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.